SELLAS Life Sciences Group, Inc. $SLS Stock: Vision Financial Markets LLC Boosts Stake

Posted by Brenda Bartman on Oct 24th, 2026

Vision Financial Markets LLC grew its stake in shares of SELLAS Life Sciences Group, Inc. (NASDAQ:SLS – Free Report) by 481.6% in the third quarter, according to its most recent disclosure with the SEC. The fund owned 57,000 shares of the company’s stock after buying an additional 47,200 shares during the period. SELLAS Life Sciences Group makes up 0.5% of Vision Financial Markets LLC’s investment portfolio, making the stock its 29th biggest holding. Vision Financial Markets LLC’s holdings in SELLAS Life Sciences Group were worth $702,000 as of its most recent filing with the SEC.

Other hedge funds have also made changes to their positions in the company. Nykredit A S acquired a new stake in SELLAS Life Sciences Group during the second quarter worth about $27,000. GAMMA Investing LLC raised its holdings in SELLAS Life Sciences Group by 293.2% in the 3rd quarter. GAMMA Investing LLC now owns 2,186 shares of the company’s stock valued at $27,000 after acquiring an additional 1,630 shares in the last quarter. California State Teachers Retirement System raised its holdings in SELLAS Life Sciences Group by 22.4% in the 1st quarter. California State Teachers Retirement System now owns 9,337 shares of the company’s stock valued at $39,000 after acquiring an additional 1,709 shares in the last quarter. Wealthfront Advisers LLC bought a new stake in shares of SELLAS Life Sciences Group in the 1st quarter worth approximately $48,000. Finally, Principal Financial Group Inc. bought a new stake in shares of SELLAS Life Sciences Group in the 1st quarter worth approximately $53,000. Institutional investors own 17.38% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research firms have recently issued reports on SLS. Alliance Global Partners restated a “buy” rating on shares of SELLAS Life Sciences Group in a research report on Wednesday, August 12th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of SELLAS Life Sciences Group in a research report on Thursday, October 15th. Two investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat, SELLAS Life Sciences Group currently has a consensus rating of “Hold” and a consensus target price of $10.00.

Read Our Latest Report on SELLAS Life Sciences Group

SELLAS Life Sciences Group Trading Up 1.7%

NASDAQ SLS traded up $0.19 on Friday, reaching $11.54. The company’s stock had a trading volume of 3,264,461 shares, compared to its average volume of 5,695,020. SELLAS Life Sciences Group, Inc. has a 52 week low of $1.39 and a 52 week high of $15.88. The firm has a market cap of $2.33 billion, a PE ratio of -54.95 and a beta of 2.56. The business has a 50-day moving average price of $12.43 and a 200 day moving average price of $10.15.

SELLAS Life Sciences Group (NASDAQ:SLS – Get Free Report) last released its quarterly earnings data on Tuesday, August 11th. The company reported ($0.05) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.04) by ($0.01).

SELLAS Life Sciences Group Profile

(Free Report)

SELLAS Life Sciences Group, Inc is a clinical-stage biopharmaceutical company focused on developing novel cancer therapies. The company’s research and development programs are centered on treatments designed to stimulate or restore the immune system’s ability to recognize and attack cancer cells, as well as targeted therapies for hematologic malignancies.

SELLAS’ lead product candidate is galinpepimut-S (GPS), a multi-peptide immunotherapeutic targeting Wilms’ tumor 1 (WT1), a protein expressed in multiple types of cancer.